

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

HIGHLY SELECTIVE CDK9 INHIBITOR “SYHX1903” OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that “SYHX1903” (the “**Product**”), independently developed by the Group, has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. Patent applications of the Product have been submitted in China and overseas.

As a highly selective cyclin-dependent protein kinase 9 (CDK9) inhibitor, the Product has great potential for the CDK9-targeted treatment of hematological malignancies and solid tumors. The indication for this clinical trial approval is hematological malignancies. Clinical trial application for advanced solid tumor indications will be filed at a later stage. The pre-clinical studies have shown that as a highly selective CDK9 inhibitor, the Product has significant efficacy in the treatment of hematological malignancies and solid tumors, good safety as well as pharmacokinetic characteristics, providing a promising prospect of demonstrating good anti-tumor efficacy in the clinical trials.

Given the favorable results of the non-clinical studies, the Group will endeavor to push forward the clinical trials of the Product and strive to launch the Product as soon as possible.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 25 May 2021

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.